CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 113 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2022. The put-call ratio across all filers is 1.24 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $38,623,960 | -17.7% | 1,214,972 | -36.9% | 0.10% | -18.6% |
| Q1 2023 | $46,950,067 | -48.1% | 1,924,972 | -32.9% | 0.12% | -52.8% |
| Q4 2022 | $90,439,405 | -3.4% | 2,867,451 | -13.5% | 0.25% | -8.8% |
| Q3 2022 | $93,635,000 | +13.7% | 3,313,333 | +6.4% | 0.27% | +22.3% |
| Q2 2022 | $82,317,000 | -24.5% | 3,113,333 | 0.0% | 0.22% | -8.9% |
| Q1 2022 | $108,998,000 | +8.0% | 3,113,333 | 0.0% | 0.25% | +30.9% |
| Q4 2021 | $100,934,000 | +9.9% | 3,113,333 | 0.0% | 0.19% | +7.4% |
| Q3 2021 | $91,843,000 | +83.8% | 3,113,333 | +59.7% | 0.18% | +88.2% |
| Q2 2021 | $49,959,000 | +86.6% | 1,950,000 | 0.0% | 0.09% | +78.8% |
| Q1 2021 | $26,774,000 | +69.7% | 1,950,000 | +104.9% | 0.05% | +62.5% |
| Q4 2020 | $15,779,000 | – | 951,700 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |